Related Experiment Video
Updated: Nov 5, 2025
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.3K
Non-Hodgkin Lymphoma Metabolism
Brian James Kirsch1,2, Shu-Jyuan Chang3, Michael James Betenbaugh2
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Advances in Experimental Medicine and Biology
|May 20, 2021
Summary
Non-Hodgkin lymphomas (NHLs) are diverse lymphoid cancers. Treatment varies by type and stage, but indolent lymphomas with metastasis present significant challenges due to a lack of standard approaches.
Area of Science:
- Hematology
- Oncology
Background:
- Non-Hodgkin lymphomas (NHLs) represent a diverse category of lymphoid neoplasms.
- The majority of lymphomas in the U.S. arise from B lymphocytes, with a smaller proportion originating from T cells.
- Treatment strategies for NHLs are contingent upon neoplastic histology and tumor stage.
Purpose of the Study:
- To outline the current understanding of Non-Hodgkin lymphomas (NHLs).
- To describe the established staging system for lymphomas.
- To review conventional treatment modalities and identify challenges in managing specific NHL subtypes.
Main Methods:
- Review of existing literature on NHL classification and treatment.
- Description of the American Cancer Society's lymphoma staging system (Stages I-IV).
- Summary of therapeutic approaches including radiation therapy and chemotherapy.
Main Results:
- Radiation therapy is effective for localized follicular and mucosa-associated lymphomas.
- Chemotherapy is the primary treatment for large-cell and high-grade lymphomas.
- Indolent lymphomas, particularly those with metastasis, pose treatment difficulties due to the absence of a standardized therapeutic protocol.
Conclusions:
- NHL treatment is highly individualized based on disease characteristics.
- Established treatments exist for localized and aggressive lymphomas.
- Further research is needed to develop effective strategies for metastatic indolent lymphomas.
